position: EnglishChannel > Sci-Tech News > Article

Preliminary data shows a new COVID-19 vaccine safe and effective

Source: International Communication Center for Science & Technology| 2020-07-03 18:01:37| Author: Li Liyun & China.org

Preliminary data from a clinical trial has shown that the vaccine developed by Chinese institutes induced high-titer antibodies in all those who had been inoculated. The result has been demonstrated though two different protocols and dosages.

Experts said that the result preliminarily suggests that the vaccine is safe and effective, taking into consideration similar products in the past and existing data on human biology.

The inactivated vaccine was jointly developed by China's National Institute for Viral Disease Control and Prevention (ICDC) and a Wuhan-based research institute affiliated with China National Biotec Group (CNBG)'s parent company Sinopharm. It is among five Chinese experimental vaccines being developed to address COVID-19, and the project has been strongly supported by the country's Ministry of Science and Technology and the National Health Commission.

Wu Guizhen, chief expert of biosecurity at Chinese Center for Disease Control and Prevention, said the development of the vaccine started on Jan. 7 upon the isolation of the novel coronavirus from samples for the first time, and the trials began on April 27 after finishing a series of preclinical studies and being approved by the National Medical Products Administration.

According to experts, the clinical trials are believed to have achieved the most ideal results among those of the kind so far, and the trials also feature the longest duration and produced the most comprehensive data. Experts said that the trial efforts have provided science-based and evaluable data for epidemic prevention and control, and China has contributed its part to developing an accessible and affordable COVID-19 vaccine.

During the development and trials, CNBG has also established the world's largest workshop for producing COVID-19 vaccines. It is now the world's only negative pressure plant for COVID-19 vaccine production that was designed in accordance with biosafety and good manufacturing practice standards and can meet emergency needs for the vaccines in quantity after being put into use. Data shows that it will be able to produce 120 million doses of such vaccines annually.

(You can also read this article at:http://www.china.org.cn/china/2020-07/01/content_76225138.htm)

Editor:余昊原

Top News

  • On July 26, China's domestically developed amphibious aircraft, the AG600 Kunlong, took off from Rizhao Shanzihe Airport on a clear day. It successfully completed its first sea-based test flight off the coast of Qingdao in Shandong province, flying for a total of 1 hour and 21 minutes.

Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright © Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com